Woodline Partners LP Buys 344,614 Shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL)

Woodline Partners LP boosted its stake in shares of Vigil Neuroscience, Inc. (NASDAQ:VIGL - Free Report) by 239.1% in the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 488,756 shares of the company's stock after buying an additional 344,614 shares during the quarter. Woodline Partners LP owned approximately 1.20% of Vigil Neuroscience worth $831,000 as of its most recent SEC filing.

Other large investors have also added to or reduced their stakes in the company. Cubist Systematic Strategies LLC lifted its position in shares of Vigil Neuroscience by 53.0% during the 4th quarter. Cubist Systematic Strategies LLC now owns 24,120 shares of the company's stock valued at $41,000 after buying an additional 8,358 shares during the last quarter. Jane Street Group LLC bought a new stake in Vigil Neuroscience in the 4th quarter valued at about $83,000. Barclays PLC raised its stake in Vigil Neuroscience by 43.6% in the 4th quarter. Barclays PLC now owns 64,049 shares of the company's stock valued at $109,000 after acquiring an additional 19,436 shares during the period. Northern Trust Corp lifted its holdings in Vigil Neuroscience by 29.0% during the fourth quarter. Northern Trust Corp now owns 64,737 shares of the company's stock valued at $110,000 after purchasing an additional 14,572 shares during the last quarter. Finally, Two Sigma Advisers LP boosted its position in Vigil Neuroscience by 243.8% during the fourth quarter. Two Sigma Advisers LP now owns 69,100 shares of the company's stock worth $117,000 after purchasing an additional 49,000 shares during the period. Hedge funds and other institutional investors own 83.64% of the company's stock.

Wall Street Analysts Forecast Growth

Several analysts have recently issued reports on the stock. JMP Securities reissued a "market perform" rating on shares of Vigil Neuroscience in a research report on Thursday, May 22nd. Citizens Jmp cut shares of Vigil Neuroscience from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 22nd. Stifel Nicolaus lowered Vigil Neuroscience from a "buy" rating to a "hold" rating and cut their price target for the stock from $11.00 to $8.00 in a report on Wednesday. Guggenheim set a $8.00 price target on Vigil Neuroscience and gave the company a "neutral" rating in a research report on Thursday, May 22nd. Finally, HC Wainwright lowered Vigil Neuroscience from a "buy" rating to a "neutral" rating and decreased their price objective for the company from $14.00 to $8.00 in a research note on Tuesday. Ten analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Vigil Neuroscience currently has an average rating of "Hold" and an average target price of $10.80.

Vigil Neuroscience Price Performance

NASDAQ:VIGL traded down $0.01 during trading hours on Thursday, hitting $7.88. The stock had a trading volume of 849,129 shares, compared to its average volume of 650,512. The firm has a market capitalization of $367.78 million, a price-to-earnings ratio of -3.83 and a beta of 1.90. The company has a 50 day simple moving average of $2.55 and a two-hundred day simple moving average of $2.39. Vigil Neuroscience, Inc. has a one year low of $1.31 and a one year high of $7.95.

Vigil Neuroscience (NASDAQ:VIGL - Get Free Report) last issued its quarterly earnings data on Wednesday, May 7th. The company reported ($0.49) EPS for the quarter, topping the consensus estimate of ($0.53) by $0.04. Equities research analysts anticipate that Vigil Neuroscience, Inc. will post -2.07 earnings per share for the current year.

Vigil Neuroscience Company Profile

Vigil Neuroscience, Inc, a clinical-stage biotechnology company, focuses on developing treatments for rare and common neurodegenerative diseases by restoring the vigilance of microglia, the sentinel immune cells of the brain. Its lead candidate is VGL101(Iluzanebart), a human monoclonal antibody agonist targeting human triggering receptor expressed on myeloid cells 2 and is in a Phase 2 trial in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP), a rare and fatal neurodegenerative disease.